FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:367-368 August 1, 2002 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Stone, G. W. PubMed Citation

To the Editor: The results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) study, reported by Stone et al. (March 28 issue),¹ convincingly validate primary stent implantation as a preferred strategy for the treatment of acute myocardial infarction. However, despite a similar incidence of the primary composite end point (death from any cause, reinfarction, revascularization, or disabling stroke) at six months between patients who received stents with abciximab (10.2 percent) and those who received stents without abciximab (11.5 percent), the study should not be misconstrued as demonstrating that the administration of abciximab during primary stenting . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.